Your browser doesn't support javascript.
loading
EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study.
Lewis, Robert A; Armstrong, Iain; Bergbaum, Carmel; Brewis, Melanie J; Cannon, John; Charalampopoulos, Athanasios; Church, A Colin; Coghlan, J Gerry; Davies, Rachel J; Dimopoulos, Konstantinos; Elliot, Charlie; Gibbs, J Simon R; Gin-Sing, Wendy; Haji, Gulam; Hameed, Abdul G; Howard, Luke S; Johnson, Martin K; Kempny, Aleksander; Kiely, David G; Lo Giudice, Francesco; McCabe, Colm; Peacock, Andrew J; Peleyeju, Oyinkansola; Pepke-Zaba, Joanna; Polwarth, Gary; Price, Laura; Sabroe, Ian; Schreiber, Benjamin E; Sheares, Karen; Taboada, Dolores; Thompson, A A Roger; Toshner, Mark R; Wanjiku, Ivy; Wort, S John; Yorke, Janelle; Condliffe, Robin.
Afiliação
  • Lewis RA; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Armstrong I; Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Bergbaum C; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Brewis MJ; National Pulmonary Hypertension Service, Royal Brompton Hospital and Imperial College, London, UK.
  • Cannon J; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
  • Charalampopoulos A; Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK.
  • Church AC; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Coghlan JG; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
  • Davies RJ; Pulmonary Hypertension Unit, Royal Free Hospital, London, UK.
  • Dimopoulos K; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
  • Elliot C; National Pulmonary Hypertension Service, Royal Brompton Hospital and Imperial College, London, UK.
  • Gibbs JSR; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Gin-Sing W; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
  • Haji G; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
  • Hameed AG; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
  • Howard LS; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Johnson MK; Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Kempny A; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
  • Kiely DG; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
  • Lo Giudice F; National Pulmonary Hypertension Service, Royal Brompton Hospital and Imperial College, London, UK.
  • McCabe C; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Peacock AJ; Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Peleyeju O; National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK.
  • Pepke-Zaba J; National Pulmonary Hypertension Service, Royal Brompton Hospital and Imperial College, London, UK.
  • Polwarth G; Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK.
  • Price L; Pulmonary Hypertension Unit, Royal Free Hospital, London, UK.
  • Sabroe I; Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK.
  • Schreiber BE; Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK.
  • Sheares K; National Pulmonary Hypertension Service, Royal Brompton Hospital and Imperial College, London, UK.
  • Taboada D; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Thompson AAR; Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Toshner MR; Pulmonary Hypertension Unit, Royal Free Hospital, London, UK.
  • Wanjiku I; Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK.
  • Wort SJ; Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK.
  • Yorke J; Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
  • Condliffe R; Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Eur Respir J ; 57(2)2021 02.
Article em En | MEDLINE | ID: mdl-32631835
Health-related quality of life (HRQoL) scores assess symptom burden in pulmonary arterial hypertension (PAH) but data regarding their role in prognostication and risk stratification are limited. We assessed these relationships using the emPHasis-10 HRQoL measure.1745 patients with idiopathic PAH (IPAH), drug-induced PAH (DPAH), heritable PAH (HPAH) (collectively "(I/D/H)PAH"), or connective tissue disease-associated PAH (CTD-PAH), who had completed emPHasis-10 questionnaires at one of six UK referral centres between 2014 and 2017, were identified. Correlations with exercise capacity and World Health Organization (WHO) functional class were assessed, and exploratory risk stratification thresholds were tested.Moderate correlations were seen between emPHasis-10 scores and 6-min walk distance (r=-0.546), incremental shuttle walk distance (r=-0.504) and WHO functional class (r=0.497) (all p<0.0001). Distribution of emPHasis-10 score differed significantly between each WHO functional class (all p<0.0001). On multivariate analysis, emPHasis-10 score, but not WHO functional class, was an independent predictor of mortality. In a risk stratification approach, scores of 0-16, 17-33 and 34-50 identified incident patients with 1-year mortality of 5%, 10% and 23%, respectively. Survival of patients in WHO functional class III could be further stratified using an emPHasis-10 score ≥34 (p<0.01). At follow-up, patients with improved emPHasis-10 scores had improved exercise capacity (p<0.0001) and patients who transitioned between risk groups demonstrated similar survival to patients originally in those risk groups.The emPHasis-10 score is an independent prognostic marker in patients with (I/D/H)PAH or CTD-PAH. It has utility in risk stratification in addition to currently used parameters. Improvement in emPHasis-10 score is associated with improved exercise capacity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Tecido Conjuntivo / Hipertensão Arterial Pulmonar / Hipertensão Pulmonar Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur Respir J Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças do Tecido Conjuntivo / Hipertensão Arterial Pulmonar / Hipertensão Pulmonar Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur Respir J Ano de publicação: 2021 Tipo de documento: Article